CFD 属于复杂的高风险金融工具，其杠杆作用可能导致投资者迅速亏损。 84% 的散户投资者因进行 CFD 交易遭受资金损失。 请您谨慎考虑自己是否了解 CFD 操作，以及是否能够接受高额亏损的风险。
US 简体中文
國家 • United States
    實體 • The products and services listed on this website are not available in this location.
    English العَرَبِيَّة Bahasa Indonesia Български Čeština Dansk Deutsch Eesti ελληνικά Español Français Hrvatski Italiano Latviešu Lietuvių Magyar Nederlands Polski Português Română Русский Slovenčina Slovenščina Suomi Svenska Tiếng Việt ไทย 简体中文 繁體中文

    交易 Mersana Therapeutics, Inc. - MRSN CFD

    -
    0%
    • 概括
    • 历史数据
    • 活动
    • 收入报表
    • 资产负债表
    • 现金流
    • 所有权
    交易条件
    价差 -
    多头隔夜费

    Long position overnight fee

    Margin. Your investment $1,000.00
    隔夜费用 -0.025457 %
    Charges from borrowed part ($-1.02)
    Trade size with leverage ~ $5,000.00
    Money from leverage ~ $4,000.00
    前往平台
    		-0.025457%
    空头隔夜费

    Short position overnight fee

    Margin. Your investment $1,000.00
    隔夜费用 0.003235 %
    Charges from borrowed part ($0.13)
    Trade size with leverage ~ $5,000.00
    Money from leverage ~ $4,000.00
    前往平台
    		0.003235%
    隔夜费时间 21:00 (UTC)
    最小交易量 1
    货币 USD
    保证金 20%
    上市交易所 United States of America
    交易费 0%

    *Information provided by Capital.com

    Mersana Therapeutics Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

    关键数据
    前收盘价* N/A
    开仓* N/A
    1 年变化* N/A
    日范围* N/A
    52 周范围 2.92-8.39
    平均交易量（10 天） 1.40M
    平均交易量（3 个月) 38.63M
    市值 860.18M
    市盈率 -100.00K
    流通股 114.39M
    收入 32.35M
    EPS -2.12
    股息（收益率 %） N/A
    贝塔 1.70
    下一个财报发布日期 Aug 7, 2023

    所有数据都是由Refinitiv提供的， 除了标有星号的数据， 这是*由 Capital.com 提供的数据

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date 平仓 Change Change (%) 開倉 High Low

    Mersana Therapeutics, Inc. Events

    时间（协调世界时） (UTC) 国家/地区 事件
    Wednesday, June 7, 2023

    时间（协调世界时） (UTC)

    13:00

    国家/地区

    US

    事件

    Mersana Therapeutics Inc at Jefferies Healthcare Conference
    Mersana Therapeutics Inc at Jefferies Healthcare Conference

    Forecast

    -

    Previous

    -
    Thursday, June 8, 2023

    时间（协调世界时） (UTC)

    14:00

    国家/地区

    US

    事件

    Mersana Therapeutics Inc Annual Shareholders Meeting
    Mersana Therapeutics Inc Annual Shareholders Meeting

    Forecast

    -

    Previous

    -
    Friday, June 9, 2023

    时间（协调世界时） (UTC)

    13:00

    国家/地区

    US

    事件

    Mersana Therapeutics Inc Annual Shareholders Meeting
    Mersana Therapeutics Inc Annual Shareholders Meeting

    Forecast

    -

    Previous

    -
    Monday, August 7, 2023

    时间（协调世界时） (UTC)

    20:00

    国家/地区

    US

    事件

    Q2 2023 Mersana Therapeutics Inc Earnings Release
    Q2 2023 Mersana Therapeutics Inc Earnings Release

    Forecast

    -

    Previous

    -
    Monday, November 6, 2023

    时间（协调世界时） (UTC)

    13:30

    国家/地区

    US

    事件

    Q3 2023 Mersana Therapeutics Inc Earnings Release
    Q3 2023 Mersana Therapeutics Inc Earnings Release

    Forecast

    -

    Previous

    -
    查看所有活動
    • 年度
    • 每季度
    2022 2021 2020 2019 2018
    总收入 26.581 0.043 0.828 42.123 10.594
    收入 26.581 0.043 0.828 42.123 10.594
    总营业费用 230.348 168.901 88.938 72.323 76.249
    销售/一般/行政费用，总计 56.963 36.888 21.902 17.283 16.334
    研究与开发 173.385 132.013 67.036 55.04 59.915
    Depreciation / Amortization
    营业收入 -203.767 -168.858 -88.11 -30.2 -65.655
    利息收入（费用），非经营净值 -0.445 -1.202 0.065 1.992 1.398
    其他，净值
    税前净收入 -204.212 -170.06 -88.045 -28.208 -64.257
    税后净收入 -204.212 -170.06 -88.045 -28.208 -64.257
    未计算非常项目前的净收益 -204.212 -170.06 -88.045 -28.208 -64.257
    净收入 -204.212 -170.06 -88.045 -28.208 -64.257
    普通股股东可获收益 (不含非经常性项目) -204.212 -170.06 -88.045 -28.208 -64.257
    普通股股东可获收益 (含非經常性項目) -204.212 -170.06 -88.045 -28.208 -64.257
    摊薄净收入 -204.212 -170.06 -88.045 -28.208 -64.257
    摊薄后加权平均股 93.6542 70.5809 61.4852 43.4921 23.0322
    扣除特别项目的每股摊薄盈利 -2.18049 -2.40943 -1.43197 -0.64858 -2.78987
    Dividends per Share - Common Stock Primary Issue
    每股正常摊薄盈利 -2.18049 -2.40943 -1.43197 -0.64858 -2.78987
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    总收入 7.802 14.688 5.573 4.284 2.036
    收入 7.802 14.688 5.573 4.284 2.036
    总营业费用 65.603 60.514 65.212 56.034 48.588
    销售/一般/行政费用，总计 18.328 14.805 14.573 14.803 12.782
    研究与开发 47.275 45.709 50.639 41.231 35.806
    营业收入 -57.801 -45.826 -59.639 -51.75 -46.552
    利息收入（费用），非经营净值 1.638 0.902 -0.172 -0.469 -0.706
    税前净收入 -56.163 -44.924 -59.811 -52.219 -47.258
    税后净收入 -56.163 -44.924 -59.811 -52.219 -47.258
    未计算非常项目前的净收益 -56.163 -44.924 -59.811 -52.219 -47.258
    净收入 -56.163 -44.924 -59.811 -52.219 -47.258
    普通股股东可获收益 (不含非经常性项目) -56.163 -44.924 -59.811 -52.219 -47.258
    普通股股东可获收益 (含非經常性項目) -56.163 -44.924 -59.811 -52.219 -47.258
    摊薄净收入 -56.163 -44.924 -59.811 -52.219 -47.258
    摊薄后加权平均股 107.515 101.095 97.6419 95.7568 79.9286
    扣除特别项目的每股摊薄盈利 -0.52238 -0.44437 -0.61255 -0.54533 -0.59125
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    每股正常摊薄盈利 -0.52238 -0.44437 -0.61255 -0.54533 -0.59125
    • 年度
    • 每季度
    2022 2021 2020 2019 2018
    流动资产总额 319.219 188.898 258.58 101.326 74.305
    现金和短期投资 280.712 177.947 255.094 99.79 70.131
    现金等价物 128.885 177.947 255.094 62.351 59.634
    应收账款总额，净额 30 0 0.459
    Accounts Receivable - Trade, Net 30 0 0.459
    Prepaid Expenses 8.507 10.951 3.486 1.536 3.715
    Total Assets 334.34 206.111 273.399 107.541 78.502
    Property/Plant/Equipment, Total - Net 14.46 14.857 12.666 4.762 2.694
    Property/Plant/Equipment, Total - Gross 22.202 22.539 20.301 11.971 9.055
    Accumulated Depreciation, Total -7.742 -7.682 -7.635 -7.209 -6.361
    Other Long Term Assets, Total 0.661 2.356 2.153 1.453 1.503
    Total Current Liabilities 91.533 47.523 30.003 24.07 69.425
    Accounts Payable 13.951 12.321 8.34 7.296 10.727
    Accrued Expenses 45.982 31.019 17.583 11.205 12.375
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 31.36 3.944 3.987 4.815 46.323
    Total Liabilities 242.283 84.37 45.312 29.223 69.707
    Total Long Term Debt 25.132 25.075 5.151 4.476 0
    Other Liabilities, Total 125.618 11.772 10.158 0.677 0.282
    Total Equity 92.057 121.741 228.087 78.318 8.795
    Preferred Stock - Non Redeemable, Net 0 0 0 0 0
    Common Stock 0.011 0.007 0.007 0.005 0.003
    Additional Paid-In Capital 746.889 572.213 508.499 270.662 172.966
    Retained Earnings (Accumulated Deficit) -654.691 -450.479 -280.419 -192.374 -164.166
    Total Liabilities & Shareholders’ Equity 334.34 206.111 273.399 107.541 78.502
    Total Common Shares Outstanding 105.145 73.7091 68.8413 45.388 23.2345
    短期投资 151.827 0 37.439 10.497
    Long Term Investments
    Other Equity, Total -0.152 0 0.025 -0.008
    Current Port. of LT Debt/Capital Leases 0.24 0.239 0.093 0.754
    Long Term Debt 24.929 24.626 4.977 4.201
    Capital Lease Obligations 0.203 0.449 0.174 0.275
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    流动资产总额 281.807 319.219 300.037 237.079 241.47
    现金和短期投资 273.919 280.712 290.126 225.128 230.057
    现金等价物 122.825 128.885 184.082 135.338 230.057
    Prepaid Expenses 7.888 8.507 9.911 11.951 11.413
    Total Assets 296.195 334.34 314.85 252.351 258.267
    Property/Plant/Equipment, Total - Net 13.8 14.46 14.197 14.548 14.55
    Other Long Term Assets, Total 0.588 0.661 0.616 0.724 2.247
    Total Current Liabilities 83.402 91.533 88.794 71.47 56.463
    Accounts Payable 18.156 13.951 13.732 8.158 9.775
    Accrued Expenses 35.492 45.982 43.901 36.848 29.879
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 29.754 31.6 31.161 26.464 16.809
    Total Liabilities 231.901 242.283 224.621 118.317 117.741
    Total Long Term Debt 25.004 24.929 24.853 24.777 24.702
    Long Term Debt 25.004 24.929 24.853 24.777 24.702
    Other Liabilities, Total 123.495 125.821 110.974 22.07 36.576
    Total Equity 64.294 92.057 90.229 134.034 140.526
    Common Stock 0.011 0.011 0.01 0.01 0.009
    Additional Paid-In Capital 775.125 746.889 700.217 684.106 638.254
    Retained Earnings (Accumulated Deficit) -710.854 -654.691 -609.767 -549.956 -497.737
    Other Equity, Total 0.012 -0.152 -0.231 -0.126
    Total Liabilities & Shareholders’ Equity 296.195 334.34 314.85 252.351 258.267
    Total Common Shares Outstanding 109.061 105.145 98.5826 97.1664 87.0731
    Property/Plant/Equipment, Total - Gross 22.202
    Current Port. of LT Debt/Capital Leases
    Preferred Stock - Non Redeemable, Net 0 0 0 0
    Accumulated Depreciation, Total -7.742
    Capital Lease Obligations
    短期投资 151.094 151.827 106.044 89.79
    应收账款总额，净额 0 30
    Accounts Receivable - Trade, Net 0 30
    • 年度
    • 每季度
    2022 2021 2020 2019 2018
    净收入/起跑线 -204.212 -170.06 -88.045 -28.208 -64.257
    经营活动产生的现金 -49.363 -139.988 -74.696 -67.744 -55.216
    经营活动产生的现金 0.927 0.855 1.01 1.245 1.257
    非现金物品 20.823 19.132 7.234 4.753 3.718
    营运资金的变化 133.099 10.085 5.105 -45.534 4.066
    投资活动产生的现金 -152.716 -0.648 37.027 -27.293 87.195
    资本支出 -2.197 -0.648 -0.473 -0.605 -1.37
    其他投资现金流量项目，总计 -150.519 0 37.5 -26.688 88.565
    融资活动产生的现金 153.017 63.646 230.412 97.704 1.064
    股票的发行（报废），净额 153.289 2.477 167.689 92.826 1.064
    现金净变化 -49.062 -76.99 192.743 2.667 33.043
    已付现金利息 2.463 0.429 0.234 0.132
    债务的发行（退还），净额 -0.272 61.428 62.723 4.878
    融资现金流项目 0 -0.259
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -56.163 -204.212 -159.288 -99.477 -47.258
    Cash From Operating Activities -29.005 -49.363 1.866 -52.731 -7.955
    Cash From Operating Activities 0.319 0.927 0.645 0.432 0.205
    Non-Cash Items 5.148 20.823 16.386 11.11 5.679
    Cash Interest Paid 0.791 2.463 1.746 1.1 0.531
    Changes in Working Capital 21.691 133.099 144.123 35.204 33.419
    Cash From Investing Activities 1.396 -152.716 -107.29 -90.799 -0.329
    Capital Expenditures -0.911 -2.197 -1.412 -0.986 -0.329
    Other Investing Cash Flow Items, Total 2.307 -150.519 -105.878 -89.813
    Cash From Financing Activities 21.549 153.017 111.559 100.921 60.394
    Financing Cash Flow Items -0.15 0 0 0 0
    Issuance (Retirement) of Stock, Net 21.764 153.289 111.766 101.063 60.47
    Issuance (Retirement) of Debt, Net -0.065 -0.272 -0.207 -0.142 -0.076
    Net Change in Cash -6.06 -49.062 6.135 -42.609 52.11
    投资者名称 投资者类型 流通股百分比 持有股份 股份变动 持有日期 换手率
    OrbiMed Advisors, LLC Investment Advisor/Hedge Fund 7.8781 9011437 0 2023-03-31 LOW
    Bain Capital Life Sciences Investors, LLC Investment Advisor 7.5741 8663673 0 2023-03-31 LOW
    Avoro Capital Advisors LLC Investment Advisor/Hedge Fund 6.6005 7550000 0 2023-03-31 LOW
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 5.6058 6412222 556161 2023-03-31 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 5.5956 6400549 15793 2023-03-31 LOW
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 4.0377 4618576 189452 2023-03-31 LOW
    Bellevue Asset Management AG Investment Advisor 3.7589 4299619 17019 2023-03-31 LOW
    Rock Springs Capital Management LP Hedge Fund 3.5877 4103803 0 2023-03-31 LOW
    Sarissa Capital Management, L.P. Hedge Fund 3.3221 3800000 -197010 2023-03-31
    Avidity Partners Management LP Hedge Fund 3.0015 3433233 3433233 2023-03-31 LOW
    Braidwell LP Hedge Fund 2.9338 3355805 1493105 2023-03-31 HIGH
    Candriam Belgium S.A. Investment Advisor/Hedge Fund 2.5902 2962848 270000 2023-03-31 LOW
    Candriam Luxembourg S.A. Investment Advisor 2.4788 2835409 0 2023-04-30 HIGH
    Marshall Wace LLP Investment Advisor/Hedge Fund 2.1827 2496710 -27274 2023-03-31 HIGH
    Invus Public Equities Advisors, LLC Investment Advisor 1.9371 2215788 15788 2023-03-31 LOW
    Baker Bros. Advisors LP Hedge Fund 1.6489 1886115 1886115 2023-03-31 LOW
    D. E. Shaw & Co., L.P. Hedge Fund 1.579 1806099 -529840 2023-03-31 LOW
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.5726 1798847 91377 2023-03-31 LOW
    Goldman Sachs Asset Management, L.P. Investment Advisor 1.5083 1725328 101999 2023-03-31 LOW
    Millennium Management LLC Hedge Fund 1.1025 1261054 -2402473 2023-03-31 HIGH

    为什么选择 Capital.com？让我们的数字来说话。

    Capital.com Group

    535K+

    交易者

    87K+

    每月活跃客户

    $113M+

    每月投资额

    $64M+

    每月提取金额

    交易计算器

    如果您在特定日期（选择一个日期）开立差价合约交易并在不同日期（选择一个日期）关闭交易，计算您的假设盈亏。

    交易佣金
    0
    • 1:1
    杠杆
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    投资
    交易规模（杠杆 x 投资）：
    開倉

    平仓

    做空 做多
    過去的表現並不是未來結果的可靠指標
    盈利/盈利/亏损

    Mersana Therapeutics, Inc. Company profile

    关于 Mersana Therapeutics Inc.

    Mersana Therapeutics, Inc.是一家处于临床阶段的生物制药公司。 该公司专注于开发抗体药物结合物（ADCs）。 公司的平台包括Dolaflexin和Dolasynthen。 其候选产品包括upifitamab rilsodotin（UpRi，XMT-1536）和XMT-1592。 公司的早期项目包括针对B7-H4的Dolasynthen ADC，XMT-1660，以及利用Immunosynthen平台的候选产品。 UpRi是一种利用公司Dolaflexin平台的ADC，针对NaPi2b，这是一种在卵巢癌和非小细胞肺癌（NSCLC）腺癌中广泛表达的抗原。 XMT-1592采用公司的Dolasynthen平台，靶向NaPi2b。

    Industry: Bio Therapeutic Drugs

    840 Memorial Dr
    CAMBRIDGE
    MASSACHUSETTS 02139
    US

    收入报表

    • Annual
    • Quarterly

    人们也观看

    BTC/USD

    26,982.95 Price
    +0.360% 1D Chg, %
    多头隔夜费 -0.0616%
    空头隔夜费 0.0137%
    隔夜费时间 21:00 (UTC)
    价差 60.00

    US100

    14,496.10 Price
    +0.270% 1D Chg, %
    多头隔夜费 -0.0255%
    空头隔夜费 0.0032%
    隔夜费时间 21:00 (UTC)
    价差 1.8

    Gold

    1,965.95 Price
    -0.690% 1D Chg, %
    多头隔夜费 -0.0183%
    空头隔夜费 0.0101%
    隔夜费时间 21:00 (UTC)
    价差 0.30

    XRP/USD

    0.52 Price
    +1.130% 1D Chg, %
    多头隔夜费 -0.0753%
    空头隔夜费 0.0069%
    隔夜费时间 21:00 (UTC)
    价差 0.00397

    还在找一位您可以信任的经纪商吗？

    加入成为全球535,000万多名交易者的一份子，选择利用Capital.com进行交易吧。

    1. 创建和验证您的账户 2. 进行存款 3. 找到适合您的交易